PA 1420

Drug Profile

PA 1420

Alternative Names: Polymyxin EI

Latest Information Update: 15 May 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron Corporation
  • Class Antibacterials; Peptide antibiotics
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 15 May 2001 Discontinued-Clinical for Cystic fibrosis-associated respiratory tract infections in USA (Inhalation)
  • 15 May 2001 Discontinued-Clinical for Pseudomonal infections in USA (Inhalation)
  • 05 Oct 2000 PathoGenesis Corporation has been acquired by Chiron Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top